Skip to content

The effect of barij deprex capsule on Depressive symptoms

The effect of barij deprex capsule containing Echium amoenum L and Hypericum perforatum dry extracts on mild to moderate Depression and comparison with fluoxetine

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017082612438N24
Enrollment
60
Registered
2017-09-26
Start date
2017-06-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive episode. Depressive episode

Interventions

Intervention 1: control: 20 mg fluoxetine capsules daily, BID, 8 weeks. Intervention 2: intervention: 350 mg barij deprex capsules, BID.8 week.
Treatment - Drugs
control: 20 mg fluoxetine capsules daily, BID, 8 weeks
intervention: 350 mg barij deprex capsules, BID.8 week

Sponsors

Barij Research Center of Medicinal Herbs
Lead Sponsor
Vice chancellor for research of Kashan University of Medical Science
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 18-55 years old; patients with mild to moderate depression based on the Hamilton scale and clinical interview based on DSM-IV-TRcriteria Exclusion criteria: Pregnancy and lactation; allergy to herbs in study; A cognitive disorder in the past year; History of bipolar disorder and other disorders Axis I(According to the SCID-I interview);  Use of psychoactive drugs in the last 2 weeks;  Severe medical conditions;  Use of psychoactive substances;  Patients with suicidal thoughts; History or use of vitamin supplements in the last 2 months; Psychotic disorders

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of depression. Timepoint: beginning, four and eight weeks after the start of the study. Method of measurement: Hamilton questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.M.Taghizadeh

Kashan University of Medical Sciences

mohsenta44@yahoo.com+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026